We observed an IDH1 or IDH2 mutation in 51 of 64 (79.7%) grade II tumors (all 51 cases were gliomas and 37 of these harbored the common p.R132H IDH1 mutation), in 36 of 46 (78.3%) grade III tumors (all 36 cases were gliomas and 31 harbored p.R132H), and in 4 of 183 (2.2%) grade IV tumors (all p.R132H). Here, IDH2 is linked to central nervous system cancer.